Insights

Gathering insights about Lumis Experience…

Similar companies to Lumis Experience

Lumis Experience Tech Stack

Lumis Experience uses 8 technology products and services including GDPR, Docker, Oracle, and more. Explore Lumis Experience's tech stack below.

GDPR
Certificates
Docker
Containerization
Oracle
Enterprise
Swiper
Javascript Libraries
HubSpot
Marketing Automation
RD Station
Marketing Automation
YouTube
Video Players
React Native
Widgets

Media & News

Alumis to Present at the Jefferies Global Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m.
May 29, 2025 | www.globenewswire.com
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
May 29, 2025 | www.globenewswire.com
Alumis Completes Merger with ACELYRIN
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned.
May 21, 2025 | www.globenewswire.com
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones.
May 14, 2025 | www.globenewswire.com
Alumis Stockholders Approve Merger with ACELYRIN
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC.
May 13, 2025 | www.globenewswire.com
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC.
Apr 21, 2025 | www.globenewswire.com
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i.
Apr 16, 2025 | www.businesswire.com

Lumis Experience's Email Address Formats

Lumis Experience uses at least 1 format(s):

Lumis Experience Email Formats	Example	Percentage
FLast@lumis.com.br	JDoe@lumis.com.br	27%
First@lumis.com.br	John@lumis.com.br	23%
FLast@lumis.com.br	JDoe@lumis.com.br	27%
First@lumis.com.br	John@lumis.com.br	23%

Frequently Asked Questions

Where is Lumis Experience's headquarters located?

Lumis Experience's main headquarters is located at Rua da Quitanda, 199 - 11 andar, Rio de Janeiro, RJ 20091-005, BR. The company has employees across 3 continents, including South AmericaEuropeNorth America.

What is Lumis Experience's stock symbol?

Lumis Experience is a publicly traded company; the company's stock symbol is ALMS.

What is Lumis Experience's official website and social media links?

Lumis Experience's official website is lumis.com.br and has social profiles on LinkedIn.

What is Lumis Experience's NAICS code?

Lumis Experience's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Lumis Experience have currently?

As of October 2025, Lumis Experience has approximately 110 employees across 3 continents, including South AmericaEuropeNorth America. Key team members include Head Comercial: R. K.Head Of Services: R. B.Co-Founder & Ceo: K. N.. Explore Lumis Experience's employee directory with LeadIQ.

What industry does Lumis Experience belong to?

Lumis Experience operates in the IT Services and IT Consulting industry.

What technology does Lumis Experience use?

Lumis Experience's tech stack includes GDPRDockerOracleSwiperHubSpotRD StationYouTubeReact Native.

What is Lumis Experience's email format?

Lumis Experience's email format typically follows the pattern of FLast@lumis.com.br. Find more Lumis Experience email formats with LeadIQ.

When was Lumis Experience founded?

Lumis Experience was founded in 2001.

Lumis Experience

IT Services and IT ConsultingBrazil51-200 Employees

Somo, há mais de 20 anos, especialista no desenvolvimento de soluções para a gestão da experiência e canais digitais de nossos clientes. 

Com o LumisXP, nossa Plataforma de Experiências Digitais DXP, nossos clientes garantem ao usuário uma experiência inovadora e hiperpersonalizada na navegação dos canais digitais. 

Com recursos de alta tecnologia para criação de conteúdo com Inteligência Artificial, criação de testes A/B em minutos, mapeamento de jornada, analytics e dashboards customizáveis e opções de hipersegmentação. 

Conheça o poder do LumisXP!

Company Overview

Headquarters: Rua da Quitanda, 199 - 11 andar, Rio de Janeiro, RJ 20091-005, BR
Website: lumis.com.br
Stock Symbol: ALMS
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 2001
Employees: 51-200

Media & News

Funding & Financials

$250M$500M
Lumis Experience's revenue is estimated to be in the range of $250M$500M

Funding & Financials

$250M$500M
Lumis Experience's revenue is estimated to be in the range of $250M$500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Lumis Experience

Lumeon

Luminary

Illuma Technology Limited

Lumeo

Solis

Lumary

Luminous

LUMINO

Lumis Experience Tech Stack

Media & News

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Lumis Experience's Email Address Formats

Frequently Asked Questions

Where is Lumis Experience's headquarters located?

What is Lumis Experience's stock symbol?

What is Lumis Experience's official website and social media links?

What is Lumis Experience's NAICS code?

How many employees does Lumis Experience have currently?

What industry does Lumis Experience belong to?

What technology does Lumis Experience use?

What is Lumis Experience's email format?

When was Lumis Experience founded?

Lumis Experience

Company Overview

Media & News

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?